Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 10/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668485 | 0.83 | SCN4A (0.59) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL19686114 | 0.83 | SCN4A (0.47) | SCN4AAKT1TACR1CACNA1FCACNA1D | |
| SCHEMBL19686104 | 0.79 | SCN4A (0.68) | SCN4AAKT1TACR1GRIN2DGRIN3B | |
| SCHEMBL19686208 | 0.75 | ALDH1A1 (0.40) | NOTUMSSTR4 | |
| SCHEMBL19686191 | 0.75 | SCN4A (0.49) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL19686196 | 0.71 | SCN4A (0.76) | SCN4AAKT1SLC6A2SLC6A4GRIN2D | |
| SCHEMBL12944891 | 0.71 | SSTR4 (0.45) | NOTUMSSTR4 | |
| SCHEMBL2394573 | 0.71 | SCN4A (0.69) | SCN4AAKT1SLC6A2SLC6A4 | |
| SCHEMBL19686108 | 0.71 | SCN4A (0.69) | SCN4AAKT1SLC6A2SLC6A4 | |
| SCHEMBL19686117 | 0.70 | SCN4A (0.63) | SCN4AAKT1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885AKT1 1612/4885TACR1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.